| 5.75 0.04 (0.7%) | 08-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.92 | 1-year : | 7.35 |
| Resists | First : | 5.92 | Second : | 6.3 |
| Pivot price | 5.67  |
|||
| Supports | First : | 5.32 | Second : | 4.42 |
| MAs | MA(5) : | 5.71 |
MA(20) : | 5.75 |
| MA(100) : | 5.67 |
MA(250) : | 7.17 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 51.3 |
D(3) : | 42.8 |
| RSI | RSI(14): 50 |
|||
| 52-week | High : | 15.78 | Low : | 3.94 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IMA ] has closed below upper band by 39.5%. Bollinger Bands are 30% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.86 - 5.88 | 5.88 - 5.9 |
| Low: | 5.47 - 5.5 | 5.5 - 5.52 |
| Close: | 5.71 - 5.75 | 5.75 - 5.79 |
ImageneBio Inc (IMA) is a biotechnology company with therapies currently undergoing human trials. The firm concentrates on creating innovative medical treatments for a variety of immune-related and inflammatory diseases. A key component of their pipeline is IMG-007, a non-depleting anti-OX40 monoclonal antibody, which is now in Phase 2b clinical studies targeting atopic dermatitis.
Wed, 05 Aug 2026
ImageneBio Reports Second Quarter 2026 Financial Results and Corporate Update on Olevaprubart Clinical Development - Quiver Quantitative
Wed, 05 Aug 2026
ImageneBio’s Atopic Dermatitis Data Anticipated in Q4 2027 - Stock Titan
Fri, 31 Jul 2026
ImageneBio, Inc. Revenue Breakdown – NASDAQ:IMA - TradingView
Mon, 27 Jul 2026
IMA|ImageneBio Ord Shs|Price:5.550|Chg%:-0.360 - TradingKey
Sat, 25 Jul 2026
ImageneBio Inc. (IMA) Q1 2026 Earnings: EPS Misses Estimates Amid Continued R&D Investment - Earnings Surprise Score - dars.gov.et
Fri, 24 Jul 2026
ImageneBio Inc. (IMA) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 11 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 11.2 (%) |
| Held by Institutions | 48.1 (%) |
| Shares Short | 394 (K) |
| Shares Short P.Month | 396 (K) |
| EPS | -4.79 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.93 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -45.7 % |
| Return on Equity (ttm) | -86.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -55 (M) |
| Levered Free Cash Flow | -27 (M) |
| PE Ratio | -1.21 |
| PEG Ratio | 0 |
| Price to Book value | 0.52 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.18 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|